Concomitant sarcoidosis and a connective tissue disease: review of the clinical findings and postulations concerning their association.

Advances in the diagnosis and treatment of sarcoidosis. F1000Prime Rep (2014) 0.96

Morbidity and mortality in sarcoidosis. Curr Opin Pulm Med (2014) 0.87

What is sarcoidosis? Respir Med (2013) 0.75

Degos disease: a C5b-9/interferon-α-mediated endotheliopathy syndrome. Am J Clin Pathol (2011) 2.50

Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma. J Rheumatol (2009) 1.78

A novel antiapoptotic role for alpha1-antitrypsin in the prevention of pulmonary emphysema. Am J Respir Crit Care Med (2006) 1.72

Clinical profile of anti-PL-12 autoantibody. Cohort study and review of the literature. Chest (2009) 1.25

Interstitial lung disease in the patient who has connective tissue disease. Clin Chest Med (2004) 1.23

Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. Thorax (2013) 1.14

Case 18-2014: A man with a rash, myalgia, and weakness. N Engl J Med (2014) 1.09

Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry. Arthritis Care Res (Hoboken) (2014) 1.03

MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trial. Arthritis Rheum (2009) 1.03

Innovative developments for long-term mammalian pest control. Pest Manag Sci (2013) 1.00

Down-regulation of collagen and connective tissue growth factor expression with hepatocyte growth factor in lung fibroblasts from white scleroderma patients via two signaling pathways. Arthritis Rheum (2007) 0.97

Pulmonary hypertension in interstitial lung disease. Curr Opin Pulm Med (2005) 0.96

Impairment of the antifibrotic effect of hepatocyte growth factor in lung fibroblasts from African Americans: possible role in systemic sclerosis. Arthritis Rheum (2007) 0.96

Pulmonary involvement in Sjögren syndrome. Clin Chest Med (2010) 0.94

Cost-utility of treatments for pulmonary arterial hypertension: a Markov state-transition decision analysis model. Clin Drug Investig (2009) 0.90

Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival. Chest (2008) 0.90

Bridging disciplines, knowledge systems and cultures in pest management. Environ Manage (2014) 0.87

Rationale for anticoagulant therapy of pulmonary fibrosis. Am J Respir Crit Care Med (2014) 0.86

Behavioral and magnetic resonance spectroscopic studies in the rat hyperserotonemic model of autism. Physiol Behav (2002) 0.85

Chronic dyspnea and severe obstruction after pneumonectomy: postpneumonectomy syndrome. Am J Med Sci (2008) 0.82

The PPARγ Agonist Rosiglitazone Is Antifibrotic for Scleroderma Lung Fibroblasts: Mechanisms of Action and Differential Racial Effects. Pulm Med (2011) 0.81

Bronchoalveolar lavage fluid in scleroderma interstitial lung disease: technical aspects and clinical correlations: review of the literature. Semin Arthritis Rheum (2009) 0.80

Critical care challenges in the adult ECMO patient. Dimens Crit Care Nurs (2005) 0.78

Chronic obstructive pulmonary disease in geriatric critical care. Crit Care Clin (2003) 0.75

Opioid associated intravenous and cutaneous microvascular drug abuse (skin-popping) masquerading as Degos disease (malignant atrophic papulosis) with multiorgan involvement. Dermatol Online J (2015) 0.75